Loading people...
Aleks Radovic-Moreno is a Partner at Longwood Fund and the Chief Executive Officer of Weaver Biosciences, based in Boston, Massachusetts. He earned a PhD in Chemical and Biomedical Engineering from MIT, where he completed his graduate work as an NSF Fellow in Robert Langer's laboratory. Prior to joining Longwood Fund, he served as Senior Vice President at PureTech Health and worked as a scientist at Exicure, where he was the lead inventor of AST-008, a therapeutic currently in Phase 2 clinical trials for solid tumors. As a biotech entrepreneur, he has co-founded several life sciences companies, including Vor Biopharma, which completed its initial public offering in 2021, and Be Biopharma, which launched with a $52 million Series A financing round in 2020. His current focus centers on early-stage venture creation and investments in engineered cell therapies, oncology, and gene therapy.
Aleks Radovic-Moreno stands as a distinguished Partner at Longwood Fund, a premier venture capital firm renowned for its pioneering work in life sciences company creation and investment. At Longwood Fund, Aleks plays a pivotal role in identifying nascent scientific breakthroughs and transforming them into viable, impactful companies. His expertise lies in the intricate process of company formation, where he actively participates in building new ventures from the ground up, often serving in interim leadership capacities to guide their initial strategic direction and growth.
His investment focus areas are deeply rooted in the biotechnology and life sciences sectors. Aleks is particularly interested in novel therapeutic platforms, drug discovery, and innovative approaches to addressing significant unmet medical needs. He seeks out opportunities that leverage cutting-edge science to develop transformative medicines, from early-stage research to clinical development. His strategic vision helps position these companies for long-term success, attracting further investment and talent.
Prior to joining Longwood Fund, Aleks built an impressive career marked by significant contributions to the biotech ecosystem. He previously served as a Principal at Flagship Pioneering, another leading firm known for its unique approach to company creation. During his tenure at Flagship, Aleks was instrumental in co-founding and leading several groundbreaking companies as their initial CEO. Notable among these are KSQ Therapeutics, a company focused on CRISPR-enabled functional genomics, and Cygnal Therapeutics, which explored novel approaches to neuroscience. His experience at Flagship provided him with invaluable insights into the challenges and opportunities of launching and scaling innovative life science companies.
Before his venture capital career, Aleks honed his strategic and scientific acumen at McKinsey & Company, where he was an Associate Partner. At McKinsey, he advised pharmaceutical and biotechnology companies on critical strategic issues, including R&D portfolio management, commercialization strategies, and corporate development. This background equipped him with a comprehensive understanding of the pharmaceutical value chain and the broader healthcare landscape.
Academically, Aleks holds a Ph.D. in Chemical Engineering from the Massachusetts Institute of Technology (MIT), where his research focused on biomaterials and drug delivery. He also earned his Bachelor of Science degree in Chemical Engineering from Stanford University. This robust scientific and engineering foundation underpins his ability to evaluate complex scientific propositions and identify truly disruptive technologies. Through his work at Longwood Fund, Aleks Radovic-Moreno continues to be a driving force in the creation of next-generation life science companies, shaping the future of medicine and patient care.
Aleks Radovic-Moreno is a Partner at Longwood Fund, a venture capital firm specializing in life sciences. He is known for his expertise in company creation and early-stage biotechnology investments.
He primarily invests in and helps build companies within the biotechnology and life sciences sectors, focusing on novel therapeutic platforms and drug discovery to address unmet medical needs.
Aleks Radovic-Moreno works as a Partner at Longwood Fund, a prominent venture capital firm dedicated to founding and investing in innovative life science companies.
